KING PHARMS
Big PharmaKING PHARMS is a major pharmaceutical company focused on Oncology, Metabolic, Infectious Disease.
KING PHARMS's Key Drugs
KING PHARMS's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).
KING PHARMS's Recent FDA Approvals
New NDA/BLA approvals for KING PHARMS over the last two years — novel drugs only, excluding generics and label supplements.
KING PHARMS's Therapeutic Areas
KING PHARMS's approved drugs and pipeline span 4 therapeutic areas, led by Oncology and Metabolic, across 0 biologic and 6 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
KING PHARMS's Top Competitors
KING PHARMS's closest competitors by therapeutic-area and drug-target overlap include Baxter, Pfizer, and Merck. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
KING PHARMS Pipeline Snapshot
Active clinical trials for KING PHARMS across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • Top drug revenue breakdown
- • Drug-level revenue analysis
Trial Catalysts
- • Oncology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (0)
Discontinued (0)
Company Info
- First Approval
- 1948-04-26
- Latest
- 2026-05-07
- Applications
- 28